Subsequent investigations revealed that ALYREF promotes platinum resistance in ovarian cancer cells by activating the Wnt/β-Catenin pathway via the NSUN2/ALYREF/LGR4 signaling axis. Here, ALYREF is linked to ovarian carcinoma.